Display options
Cite
Sagara M, Iijima T, Kase M, et al. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. J Diabetes Complications. 2021;35(5):107885doi: 10.1016/j.jdiacomp.2021.107885.
Sagara, M., Iijima, T., Kase, M., Kato, K., Sakurai, S., Tomaru, T., Jojima, T., Usui, I., & Aso, Y. (2021). Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. Journal of diabetes and its complications, 35(5), 107885. https://doi.org/10.1016/j.jdiacomp.2021.107885
Sagara, Masaaki, et al. "Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis." Journal of diabetes and its complications vol. 35,5 (2021): 107885. doi: https://doi.org/10.1016/j.jdiacomp.2021.107885
Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 06. PMID: 33602617.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 06.

Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.

Journal of diabetes and its complications

Masaaki Sagara, Toshie Iijima, Masato Kase, Kanako Kato, Shintaro Sakurai, Takuya Tomaru, Teruo Jojima, Isao Usui, Yoshimasa Aso

Affiliations

  1. Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan.
  2. Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan. Electronic address: [email protected].

PMID: 33602617 DOI: 10.1016/j.jdiacomp.2021.107885

Abstract

AIM: To investigate the relationship in people with type 2 diabetes between serum soluble dipeptidyl peptidase-4 (sDDP-4) and degree of liver fibrosis assessed as the liver stiffness measurement (LSM) and FAST (FibroScan-AST) score, both of which were measured by transient elastography (FibroScan).

SUBJECTS AND METHODS: In this cross-sectional study, we examined 115 patients with type 2 diabetes. With transient elastography (FibroScan), we assessed the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) as measures of hepatic steatosis and liver fibrosis, respectively. We calculated the FAST score, which identifies progressive non-alcoholic steatohepatitis (NASH), from CAP, LSM, and the serum aspartate aminotransferase level. Significant hepatic steatosis was defined as CAP ≥280 dB/m; and significant liver fibrosis, as LSM ≥ 8.0 kPa. LSM was divided into 3 severity levels: significant fibrosis (8.0 to <9.7 kPa); advanced fibrosis, (9.7 to <13.0 kPa); and liver cirrhosis (≥ 13.0 kPa).

RESULTS: Serum sDPP-4 correlated positively with liver enzymes, CAP, LSM, and FAST score. Multivariate analysis showed that LSM remained to be an independent factor for serum sDDP-4. Serum sDPP-4 was significantly higher in patients with LSM ≥ 8.0 kPa than in those with LSM <8.0 kPa and was significantly elevated in patients who are at risk for non-alcoholic steatohepatitis (NASH) with fibrosis (FAST score ≥ 035 or 0.67). Patients with both hepatic steatosis and liver fibrosis had the highest serum sDPP-4.

CONCLUSION: Serum sDPP-4 was strongly associated with severity of liver fibrosis evaluated by LSM and the FAST score and was markedly elevated in diabetic patients with LSM ≥ 13.0 kPa indicating probable cirrhosis.

Copyright © 2021. Published by Elsevier Inc.

Keywords: Hepatic steatosis; Liver fibrosis; Non-alcoholic fatty liver disease; Soluble DPP4; Transient elastography; Type 2 diabetes

Conflict of interest statement

Declaration of competing interest The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Publication Types